8-K: Lilly's Q3 2025 Revenue Soars 54% on Mounjaro, Zepbound

Eli Lilly and Company reported a robust 54% increase in third-quarter 2025 revenue to $17.60 billion, driven by strong demand for Mounjaro and Zepbound, and raised its full-year financial guidance.

Summary

• Worldwide revenue for Q3 2025 increased 54% year-over-year to $17.60 billion, primarily driven by a 62% increase in volume.
• Reported Earnings Per Share (EPS) for Q3 2025 increased to $6.21, up from $1.07 in Q3 2024.
• Non-GAAP EPS for Q3 2025 increased to $7.02, up from $1.18 in Q3 2024.
• Full-year 2025 revenue guidance was raised to a range of $63.0 billion to $63.5 billion.
• Full-year 2025 reported EPS guidance was raised to a range of $21.80 to $22.50, and non-GAAP EPS guidance was raised to $23.00 to $23.70.
• The incretin portfolio, including Mounjaro and Zepbound, was the primary driver of revenue growth, with Mounjaro revenue increasing 109% to $6.52 billion and Zepbound revenue increasing 184% to $3.57 billion.
• Positive Phase 3 trial results for orforglipron across type 2 diabetes and obesity were announced, with plans for global regulatory submissions for obesity by year-end.
• U.S. FDA approval was received for Inluriyo (imlunestrant) for certain adults with advanced or metastatic breast cancer.
• Significant manufacturing capacity expansions were announced, including new facilities in Virginia ($5 billion) and Texas ($6.5 billion), and an expansion of the Puerto Rico site ($1.2 billion).

Sentiment

Score: 9

Explanation: The company reported exceptional revenue and EPS growth, significantly raised its full-year guidance, achieved multiple key regulatory approvals, and made substantial investments in manufacturing and R&D, indicating very strong operational performance and future growth prospects despite some pricing pressure and litigation charges.

Positives

• Worldwide revenue increased 54% to $17.60 billion in Q3 2025, driven by a 62% increase in volume.
• Reported EPS increased to $6.21 in Q3 2025 from $1.07 in Q3 2024.
• Non-GAAP EPS increased to $7.02 in Q3 2025 from $1.18 in Q3 2024.
• Key Products revenue grew to $11.98 billion in Q3 2025.
• Mounjaro worldwide revenue increased 109% to $6.52 billion in Q3 2025.
• U.S. Zepbound revenue increased 184% to $3.57 billion in Q3 2025.
• Worldwide Verzenio revenue increased 7% to $1.47 billion in Q3 2025.
• Gross margin increased 57% to $14.59 billion, with gross margin as a percent of revenue at 82.9%, an increase of 1.9 percentage points.
• Positive results from four Phase 3 trials of orforglipron across type 2 diabetes and obesity, enabling global regulatory submissions for obesity by year-end.
• U.S. FDA approval of Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.
• U.S. FDA approval of Omvoh (mirikizumab-mrkz) as a single-injection maintenance regimen in adults with ulcerative colitis.
• European Commission marketing authorization for Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease.
• U.S. FDA's Breakthrough Therapy designation for olomorasib for certain newly diagnosed metastatic KRAS G12C-mutant lung cancers.
• Announced over $1.2 billion investment in the Puerto Rico facility to boost oral medicine manufacturing capacity.
• Plans to build a new $6.5 billion manufacturing facility for active pharmaceutical ingredients in Texas.
• Plans to build a new $5 billion manufacturing facility in Virginia.
• Partnership with NVIDIA to build an industry-leading AI supercomputer for medicine discovery and delivery.
• Full-year 2025 revenue guidance increased to $63.0 billion to $63.5 billion from $60.0 billion to $62.0 billion.
• Full-year 2025 reported EPS guidance increased to $21.80 to $22.50 from $20.85 to $22.10.
• Full-year 2025 non-GAAP EPS guidance increased to $23.00 to $23.70 from $21.75 to $23.00.

Negatives

• Lower realized prices negatively impacted U.S. revenue by 15%, partially offset by a favorable one-time adjustment in Q3 2024. Excluding this base period effect, U.S. price declined by high single digits.
• Acquired in-process research and development (IPR&D) charges of $655.7 million were recognized in Q3 2025.
• Asset impairment, restructuring, and other special charges of $364.9 million were primarily related to a litigation charge and acquisition/integration costs for Verve Therapeutics, Inc.
• The effective tax rate for Q3 2025 was unfavorably impacted by non-deductible acquired IPR&D charges and U.S. tax law changes enacted during the quarter.

Risks

• Significant costs and uncertainties in the pharmaceutical research and development process, including the timing and process of obtaining regulatory approvals.
• The impact and uncertain outcome of acquisitions and business development transactions and related costs.
• Intense competition affecting products, pipeline, or the industry.
• Market uptake of launched products and indications.
• Continued pricing pressures and the impact of actions by governmental and private actors affecting pricing, reimbursement, and patient access to pharmaceuticals.
• Safety or efficacy concerns associated with products.
• Dependence on relatively few products or product classes for a significant percentage of total revenue and a consolidated supply chain.
• The expiration of intellectual property protection for certain products and competition from generic and biosimilar products.
• The ability to protect and enforce patents and other intellectual property, and changes in patent law or regulations.
• Information technology system inadequacies, inadequate controls or procedures, security breaches, or operating failures.
• Issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages.
• Reliance on third-party relationships and outsourcing arrangements.
• Risks from the use of artificial intelligence or other emerging technologies in operations.
• The impact of global macroeconomic conditions, including uneven economic growth, trade disputes, and international tension.
• Fluctuations in foreign currency exchange rates, changes in interest rates, and inflation or deflation.
• Significant and sudden declines or volatility in the trading price of common stock and market capitalization.
• Litigation, investigations, or other similar proceedings involving past, current, or future products or activities.
• Changes in tax law and regulations, tax rates, or events that differ from assumptions related to tax positions.
• Regulatory changes, developments, and uncertainty, including regulatory oversight and actions regarding operations and products.
• Risks from the proliferation of counterfeit, misbranded, adulterated, or illegally compounded products.
• Actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations.
• Asset impairments and restructuring charges.
• Changes in accounting and reporting standards.

Future Outlook

Eli Lilly increased its full-year 2025 revenue guidance to a range of $63.0 billion to $63.5 billion, primarily driven by strong underlying business performance and foreign exchange rates. Reported EPS guidance was raised to $21.80 to $22.50, and non-GAAP EPS guidance was raised to $23.00 to $23.70. The performance margin is now expected to be in the range of 43.5% to 44.5% on a reported basis and 45.0% to 46.0% on a non-GAAP basis, reflecting the increased revenue guidance. The estimated effective tax rates remain unchanged at approximately 19% (reported) and 17% (non-GAAP).

Management Comments

• "Lilly delivered another strong quarter, with 54% revenue growth year-over-year driven by continued demand for our incretin portfolio."
• "We advanced orforglipron through four additional Phase 3 trials, enabling global obesity submissions by year-end, and we achieved U.S. FDA approval of Inluriyo (imlunestrant) marking key progress across our pipeline."
• "We continue to increase manufacturing capacity, announcing new facilities in Virginia and Texas and an expansion of our site in Puerto Rico."

Industry Context

Eli Lilly's strong performance, particularly in its incretin portfolio (Mounjaro, Zepbound), highlights the booming demand for GLP-1 agonists in the diabetes and obesity markets. The significant investments in manufacturing capacity reflect the company's strategy to meet this escalating demand and secure its leadership position against competitors like Novo Nordisk. Pipeline advancements in oncology (Inluriyo, olomorasib, Verzenio) and immunology (Omvoh, EBGLYSS, baricitinib) also demonstrate a diversified growth strategy beyond the incretin class, aligning with broader pharmaceutical industry trends of targeting high-need therapeutic areas. The partnership with NVIDIA for AI in drug discovery indicates a move towards leveraging advanced technology for R&D efficiency, a growing trend across the industry.

Comparison to Industry Standards

• Lilly's 54% revenue growth significantly outpaces the average growth rates of large-cap pharmaceutical companies, which typically range from mid-single to low-double digits. This exceptional growth is largely driven by the unprecedented demand for GLP-1 agonists like Mounjaro and Zepbound, a market segment where Lilly and Novo Nordisk are currently leading.
• The rapid expansion of manufacturing capacity with multi-billion dollar investments in Virginia ($5 billion), Texas ($6.5 billion), and Puerto Rico ($1.2 billion) is a strategic move to address supply constraints and capitalize on the immense demand for obesity and diabetes treatments. This scale of investment is comparable only to a few top-tier pharmaceutical companies responding to a blockbuster drug launch.
• The successful Phase 3 trials for orforglipron, an oral GLP-1, position Lilly to compete directly with Novo Nordisk's oral semaglutide (Rybelsus) and potentially offer a more convenient alternative, which is a key differentiator in the competitive diabetes and obesity landscape.
• The U.S. FDA approval of Inluriyo (imlunestrant) for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer adds to Lilly's oncology portfolio, competing in a crowded but high-value market segment alongside established players like Pfizer (Ibrance) and Novartis (Kisqali) in HR+/HER2breast cancer, and potentially offering a new option for ESR1-mutated patients.

Management Changes

Legal Proceedings

• A litigation charge was recognized as part of asset impairment, restructuring, and other special charges of $364.9 million in Q3 2025.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, raised guidance, pipeline advancements, and strategic manufacturing investments, likely leading to increased share value.
• Employees: Potential for job creation and stability due to manufacturing expansions and R&D investments.
• Customers/Patients: Benefit from new drug approvals (Inluriyo, Omvoh, Kisunla) and pipeline advancements (orforglipron), offering new treatment options for various diseases. Increased manufacturing capacity aims to ensure product availability.
• Suppliers: Increased demand for raw materials and services due to manufacturing expansions.
• Creditors: Strong financial health and increased revenue provide greater assurance for debt repayment.

Next Steps

• Submit orforglipron to global regulatory authorities by year-end for the treatment of obesity.
• Continue construction and operationalization of new manufacturing facilities in Virginia and Texas.
• Continue expansion of the Puerto Rico manufacturing site.
• Further development and commercialization of recently approved products like Inluriyo, Omvoh, and Kisunla.
• Ongoing R&D investments in the company's early and late-stage portfolio.

Key Dates

Recommendation

Eli Lilly delivered exceptional Q3 2025 financial results, significantly exceeding prior year performance with a 54% revenue increase and substantial EPS growth. The raised full-year guidance signals continued strong momentum. Key pipeline advancements, particularly with orforglipron for obesity, and multiple regulatory approvals (Inluriyo, Omvoh, Kisunla) de-risk future growth. Massive investments in manufacturing capacity demonstrate confidence in long-term demand for blockbuster drugs like Mounjaro and Zepbound. Despite some pricing pressures and litigation charges, the overall strategic execution and financial performance are outstanding, positioning Eli Lilly for sustained market leadership and strong shareholder returns.

Keywords

Eli Lilly, LLY, Pharmaceuticals, Biotech, Q3 2025 Earnings, Mounjaro, Zepbound, Orforglipron, Obesity, Diabetes, Oncology, Breast Cancer, Inluriyo, Alzheimer's, Kisunla, Ulcerative Colitis, Omvoh, Atopic Dermatitis, EBGLYSS, Alopecia Areata, Baricitinib, Verzenio, KRAS G12C, Olomorasib, CLL/SLL, Jaypirca, Manufacturing, R&D, FDA Approval, Financial Guidance